To know the bettertreatment for melasma skin disease intralesional tranexamic acid or glycolic acid chemical peel
Phase 4
- Conditions
- Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissueHealth Condition 2: L00-L99- Diseases of the skin and subcutaneous tissue
- Registration Number
- CTRI/2023/09/057178
- Lead Sponsor
- Madeshwari M
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients willing to participate in the study
Exclusion Criteria
Before starting the study
Pregnant & lactating mothers Patients on oral contraceptive pills, hormonal replacement therapy Active infection /inflammationPhotosensitivity disorders (SLE, porphyria) History of bleeding disorder /Anticoagulant treatment History of allergy Any other mode of treatment for melasma prior to the study
During the Study:
Develops side effects during the treatment patient wants to discontinue the treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the resolution of hyperpigmentationTimepoint: Baseline,week 4, week 8, week 12 and week 24
- Secondary Outcome Measures
Name Time Method To assess modified MASI scoreTimepoint: Baseline, week 12 and week 24